sc semaglutide Semaglo | 0.25mg Subcutaneous Injection Wet Ice Dose:10mg Semaglutide + BPC-157 (2mL)

sc semaglutide Semaglo | 0.25mg Subcutaneous Injection Wet Ice Dose:10mg Semaglutide + BPC-157 (2mL)

Semaglutide + BPC-157 (2mL) - Shell Medical

When you understand what creates these gaps, you can make smarter purchasing decisions instead of just chasing the lowest number

Wet Ice

Dose:10mg

| Research Parameter | Retatrutide | SLU-PP-332 | | :--- | :--- | :--- | | **Primary Receptor Target** | GLP-1R, GIPR, GCGR (Tri-agonist) | ERRα, ERRβ, ERRγ (Synthetic Agonist) | | **Mechanistic Class** | Multi-incretin peptide agonist | Exercise-mimetic small molecule | | **Reported Preclinical Half-Life** | ~6 days (rodent plasma models) | ~4–6 hours (in vivo rodent assays) | | **Solubility Profile** | Water-soluble (bacteriostatic water / PBS) | Lipophilic (DMSO / co-solvent buffers) | | **Typical Preclinical Model** | Diet-induced obesity (DIO) rodents, cell lines | Endurance / oxidative capacity rodent models | | **Vial Sizes Available** | Standard lyophilized peptide vials (e.g., 5mg–10mg) | Small-molecule research vials / mass units | Researchers evaluating these targets must carefully select their primary candidate based on whether cellular signaling or transcriptional remodeling of mitochondrial bioenergetics is the focus of the assay design